 |
31 Diseases |  |
34 Trials |
|
34 Trials |  |
1690 News |  |
| «12345678910111213...1819» |
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Effects of dipeptidyl peptidase-4 inhibition on portal hypertensive and cirrhotic rats. (Pubmed Central) - Feb 8, 2022
DPP-4 inhibition by linagliptin reduced portal pressure in portal hypertensive rats but not in cirrhotic rats. It may act by decreasing intra-hepatic resistance via up-regulation of hepatic nitric oxide synthase in portal hypertensive rats.
- | linagliptin / Generic mfg.
Trial completion: The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects (clinicaltrials.gov) - Feb 3, 2022
P4, N=40, Completed, Sponsor: University at Buffalo
It may act by decreasing intra-hepatic resistance via up-regulation of hepatic nitric oxide synthase in portal hypertensive rats. Active, not recruiting --> Completed
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Journal: DPP4 inhibitors: Could they be one of the solutions for COVID-19 patients with prediabetes? (Pubmed Central) - Jan 29, 2022
Moreover, DPP4 inhibitors may represent a safer option for prediabetic individuals in managing prediabetes either as a prophylactic or curative treatment for COVID-19. We envisage that beyond improved glycaemic control, the use of DPP4 inhibitors would also alleviate the cytokine storm, resulting in a reduction in the severity of COVID-19 symptoms and consequently reducing the morbidity and mortality in prediabetic COVID-19 patients.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Linagliptin, a DPP-4 inhibitor, ameliorates Aβ (1-42) peptides induced neurodegeneration and brain insulin resistance (BIR) via insulin receptor substrate-1 (IRS-1) in rat model of Alzheimer's disease. (Pubmed Central) - Jan 28, 2022
H&E and Congo red staining also exhibited neuroprotective and anti-amylodogenic effect respectively. Our study findings implies the significant effect of Linagliptin in reversing the behavioural and biochemical deficits by altering Aβ (1-42) and BIR via IRS-1 confirming one of the mechanism underlying the pathophysiology of AD.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Investigation of an artificial solution degradant of linagliptin: An undesired linagliptin urea derivative generates in sample preparation of linagliptin tablet treated by sonication in acetonitrile containing diluent. (Pubmed Central) - Jan 28, 2022
In the GMP quality control laboratories, such events may trigger undesirable out-of-specification (OOS) events. Hence, the results of this paper can help to prevent these events from happening in the first place or resolve these OOS events in GMP laboratories.
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Onglyza (saxagliptin) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Review, Journal, Adverse events: Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: A systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Jan 27, 2022
Skin lesion, especially BP, should be monitored in patients with diabetes undergoing DPP-4i treatment. Future studies should evaluate the susceptible population and develop strategies for early detection of skin-related AEs.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Analysis between Linagliptin and Azithromycin: In Vitro and In Vivo Interaction Study. (Pubmed Central) - Jan 27, 2022
Future studies should evaluate the susceptible population and develop strategies for early detection of skin-related AEs. Hence, the concomitant administration of Linagliptin and Azithromycin at a time might reduce the therapeutic effect of the formation of complexation.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: An electrochemical molecularly imprinted sensor based on CuBiO/rGO@MoS nanocomposite and its utilization for highly selective and sensitive for linagliptin assay. (Pubmed Central) - Jan 27, 2022
In the existence of interfering substances, an LNG imprinted electrode was utilized to analyze urine, human plasma, and tablet samples with adequate selectivity. The developed sensor was also illustrated for stability, repeatability, reproducibility, and reusability.
- | cefuroxime / Generic mfg., enoxaparin sodium / Generic mfg.
Journal: A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis. (Pubmed Central) - Jan 26, 2022
Medication associated with survival (anticoagulants, antihistamines, azithromycin, bronchodilators, cefuroxime, colchicine, and inhaled corticosteroids) may be candidates for future clinical trials. Drugs associated with mortality show an interaction with the underlying conditions.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: A novel compound heterozygous variant of the SLC12A3 gene in Gitelman syndrome with diabetes and the choices of the appropriate hypoglycemic drugs: a case report. (Pubmed Central) - Jan 21, 2022
We suggested that attention need to be paid to blood glucose monitoring in GS patients, especially when hypokalemia and hypomagnesemia are corrected. Besides, the insufficient blood volume and serum electrolyte disturbance should also be taken into consideration in the selecting hypoglycemic drugs for GS patients.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Linagliptin Protects Human SH-SY5Y Neuroblastoma Cells against Amyloid-β Cytotoxicity via the Activation of Wnt1 and Suppression of IL-6 Release. (Pubmed Central) - Jan 21, 2022
Furthermore, linagliptin prevented the downregulation of Wnt1 in Aβ1-42-treated cells exposed. The current findings reveal that linagliptin alleviates Aβ1-42-induced inflammation in SH-SY5Y cells, probably through the suppression of IL-6 release, and some of its benefits are mediated through the activation of the Wnt1 signaling pathway.
- || Marizev (omarigliptin) / Merck (MSD)
Clinical, Journal: Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. (Pubmed Central) - Jan 21, 2022
The current findings reveal that linagliptin alleviates Aβ1-42-induced inflammation in SH-SY5Y cells, probably through the suppression of IL-6 release, and some of its benefits are mediated through the activation of the Wnt1 signaling pathway. Administering omarigliptin as add-on therapy or switching to it from sitagliptin and linagliptin, but not vildagliptin, improves glycemic control and thus should help in decision making when selecting DPP-4is for T2D patients.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
New P4 trial: Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome (clinicaltrials.gov) - Jan 20, 2022
P4, N=75, Recruiting, Sponsor: Alexandria University
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Effect of linagliptin plus insulin in comparison to insulin alone on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 infection. (Pubmed Central) - Jan 20, 2022
P3
No major side effects were observed. The combination of linagliptin and insulin in hospitalized patients with SARS-CoV-2 infection and hyperglycemia reduced the relative risk of assisted mechanical ventilation by 74% and improved better pre and postprandial glucose levels with lower insulin requirements, and no higher risk of hypoglycemia.This study is registered at clinicaltrials.gov, number NCT04542213 on 09/03/2020.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: A Randomized Clinical Trial of Linagliptin vs. Standard of Care in Patients Hospitalized With Diabetes and COVID-19. (Pubmed Central) - Jan 18, 2022
P3
In this randomized clinical trial of hospitalized adult patients with diabetes and COVID-19 who received linagliptin, there was no difference in the time to clinical improvement compared with the standard of care. ClinicalTrials.gov, identifier NCT04371978.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy. (Pubmed Central) - Jan 18, 2022
No serious adverse reaction occurred in either group (P>0.05). Combined-modality treatment with linagliptin and irbesartan shows favorable clinical efficacy in treating diabetic nephropathy as it effectively protects the kidneys and improves kidney function by inhibiting inflammatory and oxidative stress responses.
- || Trial primary completion date: Morpheus Lung: A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (clinicaltrials.gov) - Jan 18, 2022
P1/2, N=435, Recruiting, Sponsor: Hoffmann-La Roche
Combined-modality treatment with linagliptin and irbesartan shows favorable clinical efficacy in treating diabetic nephropathy as it effectively protects the kidneys and improves kidney function by inhibiting inflammatory and oxidative stress responses. Trial primary completion date: Jun 2022 --> Feb 2022
- || metformin / Generic mfg.
Clinical, Journal, HEOR: Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China. (Pubmed Central) - Jan 15, 2022
The most influential parameters were the cost of DPP-4 inhibitors and their treatment efficacy. These results suggested that alogliptin was a preferred treatment option compared with other DPP-4 inhibitors for Chinese patients whose T2DM are inadequately controlled on metformin monotherapy.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Analysis of the Clinical Characteristics of Dipeptidyl Peptidase-4 Inhibitor-Induced Bullous Pemphigoid. (Pubmed Central) - Jan 8, 2022
These results suggested that alogliptin was a preferred treatment option compared with other DPP-4 inhibitors for Chinese patients whose T2DM are inadequately controlled on metformin monotherapy. DPP4i drugs are related to the occurrence of BP in diabetic patients, especially elderly men taking vildagliptin.
- ||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal, Adverse events, Real-world evidence: Comparison of Adverse Kidney Outcomes With Empagliflozin and Linagliptin Use in Patients With Type 2 Diabetic Patients in a Real-World Setting. (Pubmed Central) - Jan 8, 2022
Empagliflozin users were at a lower risk of developing AKI and exhibited a smaller eGFR decline than linagliptin users. Thus, empagliflozin may be a safer alternative to linagliptin for T2DM patients.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Linagliptin Protects against Endotoxin-Induced Acute Kidney Injury in Rats by Decreasing Inflammatory Cytokines and Reactive Oxygen Species. (Pubmed Central) - Jan 6, 2022
In the histopathology and immunohistochemistry examinations of the rat kidneys, linagliptin (10 mg/kg) suppressed nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and inducible nitric oxide synthase (iNOS), decreased injury scores, and preserved E-cadherin expression from LPS damage. In conclusion, linagliptin ameliorated endotoxin-shock-induced AKI by reducing ROS via AMPK pathway activation and suppressing the release of TNF-α and IL-1β in conscious rats.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Review, Journal: A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. (Pubmed Central) - Jan 1, 2022
In the past few years, researchers had applied various approaches to synthesize potent DPP-4 inhibitors as antidiabetic agent without side effects like weight gain, cardiovascular risks, retinopathy etc. This review will also emphasize the recent strategies and rationale utilized by researchers for the development of DPP-4 inhibitors. This review also reveals about the various other approaches like molecular modelling, ligand based drug designing, high throughput screening etc. are used by the various research group for the development of potential DPP-4 inhibitors.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Journal: A RAPID LC-PDA METHOD FOR THE SIMULTANEOUS QUANTIFICATION OF METFORMIN, EMPAGLIFLOZIN AND LINAGLIPTIN IN PHARMACEUTICAL DOSAGE FORM. (Pubmed Central) - Dec 30, 2021
This review also reveals about the various other approaches like molecular modelling, ligand based drug designing, high throughput screening etc. are used by the various research group for the development of potential DPP-4 inhibitors. The validated (as per ICH guidelines) rapid method can be routinely used in quality control lab for the quantification of metformin, empagliflozin and linagliptin in raw materials as well as in pharmaceutical dosage form.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Een onderonsje onder vrienden. (Twitter) - Dec 17, 2021
- |||||| Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Trulicity (dulaglutide) / Eli Lilly
New trial: BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes (clinicaltrials.gov) - Dec 16, 2021
P=N/A, N=550000, Recruiting, Sponsor: Brigham and Women's Hospital
- || Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Retrospective data, Review, Journal: Effects of oral antidiabetic drugs and glucagon-like peptide-1 receptor agonists on left ventricular diastolic function in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. (Pubmed Central) - Dec 16, 2021
In addition, when the effects on left ventricular diastolic function were evaluated across drugs, liraglutide alone caused a significant improvement in left ventricular diastolic function compared with OADs (sitagliptin, linagliptin, pioglitazone, rosiglitazone, voglibose, and glimepiride). From the perspective of preventing the onset of heart failure, the administration of liraglutide for type 2 diabetes is promising.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. (Pubmed Central) - Dec 16, 2021
P3
From the perspective of preventing the onset of heart failure, the administration of liraglutide for type 2 diabetes is promising. In the DYDA 2 patients the addition of linagliptin to stable diabetes therapy was safe and provided a modest non-significant increase in left ventricular systolic function measured as midwall fractional shortening.
- | metformin / Generic mfg.
Journal: Analysis of Metformin and Five Gliptins in Counterfeit Herbal Products: Designs of Experiment Screening and Optimization. (Pubmed Central) - Dec 16, 2021
Design-of-experiment, PB, and BB designs were used. Method validation was also performed in accordance with the International Conference on Harmonization guidelines.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Onglyza (saxagliptin) / AstraZeneca, Jardiance (empagliflozin) / Eli Lilly, Boehringer Ingelheim
Clinical, Journal: Pharmacotherapy of diabetes mellitus in patients with heart failure - a nation-wide analysis of contemporary treatment. (Pubmed Central) - Dec 14, 2021
In correspondence with other registries, metformin was used mostly. A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: LINAGLIPTIN AND GLICLAZIDE DI-LOADED EXTENDED-RELEASE NANOPARTICLES: FORMULATION AND EVALUATION. (Pubmed Central) - Dec 6, 2021
A positive trend was observed in prescription of DDP-4 and SGLT-2 inhibitors, while there was a significant decrease in patients taking sulfonylureas. The formula GHX1 which containing (0.5:1 xanthan gum: drugs) was the best nanoparticles formula which released more than 80% of both drugs after 8 h and could achieve good extended release over 24 h.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
नमस्ते भिक मंगे पिक्चर आरही हैं 10rs टिकट लिखना गुनाह हैं सब लिख के रखा हैं Trajenta शाबास और लूटो (Twitter) - Dec 4, 2021
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Stromal cell-derived factor-1α predominantly mediates the ameliorative effect of linagliptin against cisplatin-induced testicular injury in adult male rats. (Pubmed Central) - Nov 29, 2021
These results provided mechanistic insights into the ameliorative effect of LG on CP-induced testicular injury, through activation of SDF-1α/CXCR4 signaling pathway. Our findings suggest that LG can be a promising therapeutic candidate for CP-induced testicular injury.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant. (Pubmed Central) - Nov 29, 2021
In this retrospective analysis, linagliptin seems to be safe and efficacious after kidney transplantation. It can be considered as a treatment option to manage DM after transplantation.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Linagliptin Inhibits Interleukin-6 Production Through Toll-Like Receptor 4 Complex and Lipopolysaccharide-Binding Protein Independent Pathway in vitro Model. (Pubmed Central) - Nov 12, 2021
Concentration-dependent and -independent inflammatory suppression was observed following linagliptin treatment after LPS induction in an experimental model of TLR4 inhibition by anti-TLR4 antibodies. Our results showed that linagliptin may inhibit inflammation through multiple mechanisms centered around the TLR-4-mediated pathway.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Je kunt inderdaad uit pure halsstarrigheid ervoor kiezen de onderontwikkelde Belg te blijven. (Twitter) - Nov 10, 2021
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle. (Pubmed Central) - Nov 10, 2021
P4
The differences in pancreatic β-cell function persisted also after pairing groups for basal AUCGluc. The addition of linagliptin to patients with persistent IGT after 12 months of treatment with metformin and lifestyle, improved glucose levels during OGTT and pancreatic β-cell function after 6 months of treatment.Trial registration: Clinicaltrials.gov with the ID number NCT04088461.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Het zijn onverenigbare en totaal overbodige migranten uit zwaar onderontwikkelde en ongeciviliseerde faalstaten. Jij bent de personificatie van de slavenmoraal en van het cultuurmarxisme (alle migranten zijn (zielige) "onderdrukte slachtoffers"). (Twitter) - Nov 9, 2021
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Prandimet (repaglinide/metformin) / Novo Nordisk
Clinical, Review, Journal: Long-term efficacy and safety of anti-hyperglycaemic agents in new-onset diabetes after transplant: Results from outpatient-based 1-year follow-up and a brief review of treatment options. (Pubmed Central) - Nov 7, 2021
Combination therapy was needed in most within 1-year. Linagliptin monotherapy was effective, without producing hypoglycaemia or weight gain.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Januvia (sitagliptin) / Merck (MSD)
Clinical, Journal: Gliptin-Induced Bullous Pemphigoid: Canadian Case Series of 10 Patients. (Pubmed Central) - Nov 6, 2021
Physicians should be aware of this potential adverse effect, as gliptin-induced BP can be reversible once identified and the responsible medication is stopped. Early withdrawal of the offending drug and proper treatment can lead to rapid improvement and reduced morbidity.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Preclinical, Journal: Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice. (Pubmed Central) - Nov 6, 2021
Because combination treatment did not further improve weight loss and glucose tolerance in DIO mice, this suggests that potential negative modulatory effects of DPP-IV inhibitors on endogenous Y2R peptide agonist activity is likely insufficient to influence weight homeostasis. Weight-neutrality of DPP-IV inhibitors may therefore not be explained by counter-regulatory effects on PYY/NPY responses.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: A Single Second Shell Amino Acid Determines Affinity and Kinetics of Linagliptin Binding to Type 4 Dipeptidyl Peptidase and Fibroblast Activation Protein. (Pubmed Central) - Nov 5, 2021
Co-structures of linagliptin with DPP-4 or FAP were similar except for one second shell amino acid difference: Asp663 (DPP-4) and Ala657 (FAP). The distinct pH dependence of enzymatic activities, differences in binding affinity and kinetics of linagliptin for DPP-4 and FAP are dependent on this single amino acid difference.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Electrochemical Detection of Linagliptin and its Interaction with DNA (Pubmed Central) - Nov 2, 2021
Based on the observations, Lin has a toxic effect on DNA. We successfully demonstrated that Lin interacts with DNA, and its influence on DNA could play a vital role in the medical effect of the drug.
- || Clinical, Journal: Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. (Pubmed Central) - Oct 27, 2021
In general, the CVOTs and other safety data do not reveal serious warning signals except for saxagliptin (higher risk of hospitalization from heart failure [hHF]), although there is no robust data on the risk of hHF among patients with moderate to severe HF at baseline treated with other gliptins. This review critically appraises the efficacy and cardiovascular safety of DPP-4 inhibitors to empower clinicians to use this class of antidiabetic medications judiciously.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: Plasma Nitrate Levels Are Related to Metabolic Syndrome and Are Not Altered by Treatment with DPP-4 Inhibitor Linagliptin: A Randomised, Placebo-Controlled Trial in Patients with Early Type 2 Diabetes Mellitus. (Pubmed Central) - Oct 25, 2021
With stable vegetable intake, nitrate and nitrite, TFT, adipokines and CRP did not change after 26 weeks of linagliptin treatment. While plasma nitrate is inversely associated with MetS, linagliptin treatment does not significantly influence nitrate and nitrite concentrations, oxidative stress, adipose tissue function and systemic inflammation.
- || Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Clinical, Retrospective data, Review, Journal: Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. (Pubmed Central) - Oct 22, 2021
This analysis was limited by the scarcity of data for kidney safety endpoints in large, randomized clinical trials. Although the heterogeneity statistic was low, there are slight differences in study design and baseline demographic characteristics across trials.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Invokana (canagliflozin) / J&J, Daiichi Sankyo, Mitsubishi Tanabe
Journal: Application of experimental design in HPLC method optimization and robustness for the simultaneous determination of Canagliflozin, Empagliflozin, Linagliptin and Metformin in tablet. (Pubmed Central) - Oct 22, 2021
Satisfactory results were obtained by analysis of tablets applying the developed method. Therefore, it could be performed for the analysis of the cited drugs in quality control laboratories.
- || Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal: The Renoprotective Effect of Linagliptin in Type 2 Diabetic Patients with Severely Increased Albuminuria. (Pubmed Central) - Oct 22, 2021
Linagliptin may serve as a renoprotective therapeutic option in diabetic patients with severely increased albuminuria due to its role in proteinuria reduction. Results of this study can be used for future large-scale, long-term studies investigating the renoprotective effects of linagliptin in patients with diabetic nephropathy. DOI: 10.52547/ijkd.6110.
- Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
[VIRTUAL] Regulation of SARS CoV-2 Host Factors in the Kidney and Heart in Rats with 5/6 Nephrectomy: Effects of Salt, ARB, Dipeptidyl Peptidase 4 Inhibitor, and SGLT-2 Blocker () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_1712;
Conclusion Overall, our study indicated that there is no upregulation regarding host factors potentially promoting SARS CoV-2 virus entry into host cells when the SGLT2 inhibitor empagliflozin, telmisartan and the DPP4 blocker linagliptin are used. The results obtained in a preclinical, experimental non-diabetic kidney failure model need confirmation in ongoing interventional clinical trials.
- | Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
Journal: Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation. (Pubmed Central) - Oct 13, 2021
In conclusion, linagliptin improves left ventricular stiffness in obese ZSF1 rats by preventing direct DPP4-mediated titin cleavage, as well as by modulating both titin isoform levels and phosphorylation. Reducing left ventricular stiffness by administering linagliptin might prevent MetS-induced early diastolic dysfunction in human.
- | New trial: ON TARGET DM: Comparison of Type 2 Diabetes Pharmacotherapy Regimens (clinicaltrials.gov) - Oct 10, 2021
P=N/A, N=270000, Recruiting, Sponsor: Kaiser Permanente